While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

Roughly a year and a half after the introduction of a damning shareholder lawsuit, Amgen has lost its bid to toss the case ...

After a relatively quiet stretch, Aspen Neuroscience is rolling out a major upgrade to its in-house manufacturing. | Aspen is ...

As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...

Lucid is planning on bringing #CheckYourFoodTube events to more ex-NFL stars in cities across the U.S., with a goal of ...

Under the new cooperation deal, Recipharm gets access to Exela’s manufacturing plant in Lenoir, North Carolina. Exela is ...

Looking back over Verrica's second-quarter financial results released in August, it's easy to spot the problem. Selling, ...

No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...

On the same day that Johnson & Johnson confirmed layoffs at its home base in New Jersey | Officials in Wilson, North Carolina ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound ...